• RG7388 and the p53-MDM2 Axis: Strategic Leverage for Transla

  2026-04-25

  This thought-leadership article provides an advanced synthesis of mechanistic insight and translational strategy revolving around RG7388 (a potent, selective oral MDM2 antagonist) and its role in p53 pathway activation, cancer cell apoptosis induction, and therapy sensitization. By integrating recent biomarker discoveries—specifically the MDM1-p53-apoptosis axis in chemoradiotherapy sensitivity—this piece delivers actionable guidance for translational researchers, highlighting experimental best practices, clinical implications, and a differentiated, forward-looking perspective that builds on but goes beyond standard product information.

• Cambinol: Bridging SIRT1/2 Inhibition to CNS Injury Repair

  2026-04-24

  This thought-leadership article illuminates the emerging intersection between SIRT1/2 inhibition and central nervous system (CNS) injury research, centering on the multifaceted capabilities of SIRT1/2 Inhibitor IV (cambinol). Drawing from recent advances that link SIRT1-regulated lactylation to astrocyte polarization post-injury, we synthesize mechanistic insights, translational workflows, and evidence-driven protocols. The discussion situates cambinol within the evolving landscape of metabolic-epigenetic therapeutics, offering actionable guidance to researchers aiming to leverage its dual relevance in oncology and CNS repair.

• BFH772 (VEGFR2 inhibitor): Technical Guide and Protocol Para

  2026-04-24

  BFH772 is a potent, selective VEGFR2 inhibitor optimized for research applications that require precise modulation of VEGFR2-mediated angiogenesis, particularly in tumor models. It should not be used in workflows demanding water-soluble compounds or broad-spectrum kinase inhibition, given its defined solubility and selectivity characteristics.

• Cell Cycle Assay Kit (K2263): DNA Content Analysis & Apoptos

  2026-04-23

  The Cell Cycle Assay Kit (Catalog No. K2263) enables precise analysis of cell cycle phases G0/G1, S, and G2/M via propidium iodide DNA staining. Its robust, reproducible performance supports advanced cell cycle progression analysis and apoptosis detection by sub-G1 peak in cancer research. The kit is validated for high-specificity flow cytometry applications.

• Wallichinine Overcomes ABCB1-Mediated Multidrug Resistance i

  2026-04-23

  The referenced study demonstrates that wallichinine, a natural compound from Piper wallichii, effectively reverses multidrug resistance (MDR) mediated by ABCB1 in cancer cells. By blocking ABCB1 drug efflux and enhancing chemotherapeutic efficacy, this research offers promising directions for overcoming MDR in oncology.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor in Redox R

  2026-04-22

  GKT137831 sets a new standard as a selective dual NADPH oxidase Nox1/Nox4 inhibitor for oxidative stress and fibrosis modeling. Its high specificity and translational impact empower vascular, liver, and metabolic disease workflows, with reliable protocols and troubleshooting insights for reproducible results.

• GI 254023X: High-Selectivity ADAM10 Inhibitor for Vascular R

  2026-04-22

  GI 254023X is a potent, selective ADAM10 inhibitor with >100-fold selectivity over ADAM17, enabling precise modulation of Notch1 signaling and vascular barrier integrity. Its activity is validated in apoptosis induction in Jurkat cells and protection against Staphylococcus aureus α-hemolysin–mediated endothelial disruption. This article details the evidence, protocols, and limitations for translational research.

• Cisplatin (CDDP) in Cancer Research: Applied Workflows & Tro

  2026-04-21

  Cisplatin (CDDP) remains a gold-standard inducers of DNA crosslinks and apoptosis for cancer models, but maximizing its impact requires nuanced protocol optimization and troubleshooting. This guide delivers actionable, literature-driven strategies for in vitro and in vivo assays, including novel insights into chemoresistance uncovered by recent STAT3/ZNF263 studies.

• Strategic Assay Optimization with JNJ-26854165 (Serdemetan)

  2026-04-21

  Explore how JNJ-26854165 (Serdemetan) enables precision assay design in cancer research. This article uniquely bridges advanced in vitro methodology with practical workflow decisions for anti-proliferative and apoptosis-focused studies.

• KPT-330 (Selinexor): Optimizing CRM1 Inhibition for Cancer R

  2026-04-20

  KPT-330 (Selinexor) enables precise inhibition of nuclear export in cancer models, driving apoptosis and tumor growth suppression. This article details use-case strategies, protocol enhancements, and troubleshooting tips that empower researchers to maximize the impact of CRM1 inhibition in translational oncology.

• JNK-IN-7: Precision Tools for JNK Pathway and Apoptosis Rese

  2026-04-20

  This article provides translational researchers with a mechanistic and strategic exploration of JNK-IN-7, a selective JNK inhibitor, emphasizing its role in dissecting MAPK signaling, apoptosis, and innate immune modulation. Drawing on recent literature—including the distinct apoptotic pathways in bovine mastitis—this piece delivers actionable guidance, contrasts JNK-IN-7 with alternative tools, and highlights the unique value of APExBIO’s compound for advanced cellular signaling studies.

• LLY-507: Precision SMYD2 Inhibitor for Cancer & Fibrosis Ass

  2026-04-19

  LLY-507 empowers researchers with exceptional selectivity and nanomolar potency for dissecting SMYD2-driven pathways in cancer and fibrosis. Its proven performance in both oncology and renal disease models sets a new benchmark for epigenetic inhibitor workflows.

• Structural Basis for PSS2 Regulation of SREBP Pathways in Ce

  2026-04-18

  This study elucidates the molecular mechanism by which human phosphatidylserine synthase 2 (PSS2) selectively uses phosphatidylethanolamine (PE) as a substrate and exerts a distinct, inhibitory effect on SREBP-1/2 cleavage. The findings, supported by cryo-EM structure and lipidomics analysis, reveal functional divergence between homologous PSS1 and PSS2, providing insight into phospholipid regulation and cholesterol homeostasis.

• Angiotensin III (human, mouse): Advanced Receptor Profiling

  2026-04-17

  Explore the multifaceted role of Angiotensin III (human, mouse) in receptor signaling and its emerging links to viral pathogenesis. This article uniquely combines peptide structure, mechanistic depth, and translational implications for cardiovascular and infectious disease research.

• Ibuprofen in Cancer Research: Protocols, Performance & Pitfa

  2026-04-16

  APExBIO's Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) stands out as an anti-proliferative agent for colon cancer research, enabling precise apoptosis and cell cycle assays. This guide delivers evidence-based workflows, comparative insights, and troubleshooting strategies for maximizing experimental reproducibility.

16742 records 1/1117 page Next 12345 下5页 Last page